Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-CD276, ABBV-155 Vector   (CAT#: GTVCR-WQ148MR)

This product GTVCR-WQ148MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting CD276. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-CD276, ABBV-155 Vector (GTVCR-WQ148MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1261MR IVTScrip™ pSP6-VEE-mRNA-Anti-HBV, GC-1102 Vector Vector GC-1102
GTVCR-WQ1680MR IVTScrip™ pT7-VEE-mRNA-Anti-FN, L19-131 I Vector Vector L19-131 I
GTVCR-WQ1947MR IVTScrip™ pT7-VEE-mRNA-Anti-LAG3&PDCD1, MGD-013 Vector Vector MGD-013
GTVCR-WQ1549MR IVTScrip™ pSP6-VEE-mRNA-Anti-MUC1, IMMU-107 Vector Vector IMMU-107
GTVCR-WQ679MR IVTScrip™ pT7-VEE-mRNA-Anti-IL23A, BI 655066 Vector Vector BI 655066
GTVCR-WQ636MR IVTScrip™ pT7-VEE-mRNA-Anti-CEACAM6, BAY-1834942 Vector Vector BAY-1834942
GTVCR-WQ1625MR IVTScrip™ pSP6-VEE-mRNA-Anti-KLRK1, JNJ-64304500 Vector Vector JNJ-64304500
GTVCR-WQ1703MR IVTScrip™ pT7-VEE-mRNA-Anti-SELP, LC1004-002 Vector Vector LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW